Bioventix
Update in progressBVXP.L (LSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Bioventix PLC develops, manufactures, and supplies sheep monoclonal antibodies for diagnostic use worldwide. Its portfolio includes purified SMAs for thyroid, vitamin D, cardiac markers, drugs of abuse, fertility, oncology, and other indications; and Pyrene HOP-G ELISA and lateral flow kits for monitoring human exposure and at-risk individuals without lab access. It also offers contract SMA services and an industrial and environmental biomonitoring platform to speed results. Founded 2003, in Farnham, UK.
Company score
- Sentiment
- -0.27
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- -0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketLSE (LSE)
- LocationUnited Kingdom
- CEOMr. Peter John Harrison MA
- Founded2003
- Employees12
- Websitewww.bioventix.com
Identifiers
- ISINGB00B4QVDF07